Introduction {#S1}
============

Lung cancer is one of the malignant tumors that seriously endanger human health worldwide. The morbidity of lung cancer accounts for 11.6%, ranking first of all cancers, and 18.4% of the total number of cancer deaths are lung cancer ([@B5]). Non-small cell lung cancer (NSCLC) accounts for 80% of total lung cancer and is the most common histological type of lung cancer ([@B19]). Lung adenocarcinoma (LUAD) accounts for ∼40% of all lung cancers, which is the most aggressive pathological type of NSCLC, and is an important cause of death from respiratory cancer ([@B37]). Compared with different types of lung cancers, LUAD has slower growth and no specific clinical manifestations in its early stage. It is easy to misdiagnosis because of the similar symptoms of common respiratory diseases ([@B21]; [@B3]). Approximately 75% of patients are diagnosed with metastatic or advanced cancer and often lose the opportunity for radical surgery. With the improvements of modern clinical diagnostic methods, the survival rate is still unsatisfactory, only ∼15%, although the overall survival rate and the quality of life have been improved ([@B45]; [@B11]). In recent years, in addition to improving the treatment of lung cancer patients, searching for effective tumor markers to guide clinical diagnosis has become a hot spot in LUAD research.

Secreted phosphoprotein 1 (SPP1), also known as osteopontin, is a secretory phosphorylated glycoprotein rich in arginine--glycine--aspartic acid sequence (RGD domain) ([@B57]). It is a widely expressed mucoprotein, which can be detected in normal tissues, body fluids, and cells ([@B27]). SPP1 also participates in the regulation of physiological processes such as development, differentiation, inflammation, and the wound healing ([@B9]). In addition, more and more evidence showed that SPP1 was highly expressed in various kinds of tumors and plays a considerable role in the occurrence and metastasis of various tumors ([@B20]; [@B26]; [@B60]; [@B61]). The aim of this research was to explore the relevance between SPP1 and clinicopathological features of patients with LUAD and to determine whether it can be used as an independent prognostic marker of LUAD.

Materials and Methods {#S2}
=====================

Cancer Cell Line Encyclopedia Analysis {#S2.SS1}
--------------------------------------

Cancer Cell Line Encyclopedia (CCLE^[1](#footnote1){ref-type="fn"}^) is a database of cancer cell lines maintained by the Broad Institute of MIT & Harvard, which is an open-access database including the RNA-Seq data for the current 1,457 cancer cell lines ([@B2]). We used CCLE database to analyze the messenger RNA (mRNA) expression levels of the SPP1 in various kinds of cancer cell lines.

SPP1 mRNA Expressions in Normal Lung Tissues and LUAD Tissues {#S2.SS2}
-------------------------------------------------------------

To compare the mRNA expression levels of SPP1 in LUAD with normal lung tissues, Gene Expression Omnibus (GEO^[2](#footnote2){ref-type="fn"}^) database was employed for analyses. The mRNA expression levels were shown as the intensity of log~2~ median centered, and the SPP1 mRNA expression levels in LUAD tissues were compared with that in control normal lung tissues by Mann--Whitney *U* test. There were seven datasets that were used to compare the SPP1 expression in normal lung tissue and LUAD, including GSE2514 (20 LUAD samples and 19 normal lung tissue samples) ([@B46]), GSE7670 (20 LUAD samples and 30 normal lung tissue samples) ([@B48]; [@B7]), GSE10072 (58 LUAD samples and 49 normal lung tissue samples) ([@B22]), GSE19188 (45 LUAD samples and 65 normal lung tissue samples) ([@B16]), GSE31210 (226 LUAD samples and 20 normal lung tissue samples) ([@B38]; [@B59]), GSE32863 (58 LUAD samples and 58 normal lung tissue samples) ([@B43]), and GSE83227 (132 LUAD samples and 17 normal lung tissue samples) ([@B4]) from the GEO database. Each dataset was downloaded in Series Matrix File (s) format. The preprocess of each dataset adopted the original author's preprocessing results.

The Human Protein Atlas Analysis {#S2.SS3}
--------------------------------

The protein levels of SPP1 expression in LUAD samples and normal lung samples from the Human Protein Atlas (HPA)^[3](#footnote3){ref-type="fn"}^ database were analyzed by the immunohistochemistry (IHC) staining data ([@B52], [@B54], [@B53]). These data were then used to analyze the correlation between the mRNA levels of SPP1 expression and prognosis. The expression levels could be divided into four categories: high, medium, low, and not detected by the scoring system, which consists of the proportion of stained cells (\>75, 25--75, or \<25%) and the intensity of staining (strong, moderate, weak, or negative).

Data Mining From the GEO Database {#S2.SS4}
---------------------------------

GSE68465, including 19 normal lung tissues and 443 LUAD samples, was downloaded from the GEO database. GSE68465 was performed on GPL96 ([@B44]). A large amount of clinicopathological information, such as gender, age, and tumor--node--metastasis (TNM) stage, was collected from the database as well. The associated probe for SPP1 was 209875_s\_at. We then analyzed the survival information of samples with GSE68465 using the Kaplan--Meier method. GSE68465 were normalized by the MAS5 algorithm and log~2~ transformation were conducted.

TIMER Analysis {#S2.SS5}
--------------

Tumor Immune Estimation Resource (TIMER)^[4](#footnote4){ref-type="fn"}^ systematically analyzed the comprehensive resource of immune infiltrates in multiple tumor types, including six types of immune infiltrates (CD4^+^ T cells, B cells, CD8^+^ T cells, macrophages, neutrophils, and dendritic cells) ([@B23]; [@B25]). We selected the parameters: "Gene," gene symbol: "SPP1," cancer types: "LUAD (lung adenocarcinoma)," immune infiltrates: "Default" to explore the relationship between the SPP1 expression and the proportion of immune infiltration. We selected the parameters "survival," cancer types: "LUAD (Lung Adenocarcinoma)," clinical: (optional): "all," Immune infiltrates: "Default," gene symbol: "SPP1" to conduct survival analysis and build a multivariable Cox proportional hazards model. This model was fitted by the function coxph() using R package "survival." Baseline variables considered to be univariate with outcome or clinically relevant to the results were included into multivariable Cox proportional hazards model ([@B47]).

Gene Set Enrichment Analysis {#S2.SS6}
----------------------------

Gene Set Enrichment Analysis (GSEA) was used for gene enrichment analysis ([@B36]; [@B49]). GSE68465 was included in GSEA, and lung cancer tissue samples were divided into low- and high-expression groups according to the median expression level of SPP1. The hallmark gene set in MSigDB database was used as reference gene set. The default weighted enrichment statistical method was applied to enrichment analysis, and the number of the gene set permutation for each analysis was set as 1,000 times. Pathways with false discovery rate (FDR) *q* \< 0.25 and nominal *P* \< 0.05 were considered as significantly enriched pathways.

Validation in the Cancer Genome Atlas Dataset {#S2.SS7}
---------------------------------------------

FPKM-UQ normalized mRNA expression of The Cancer Genome Atlas (TCGA)-LUAD and clinical data were downloaded from the GDC Data Portal^[5](#footnote5){ref-type="fn"}^, and then, we screened the samples based on the complete survival information and gene expression data. The TCGA-LUAD gene expression data were processed by log~2~ transformation to compare the expression levels of SPP1 in normal lung tissue samples (*N* = 59) and LUAD samples (*N* = 504). According to the expression level of SPP1, the samples above the median expression level were set as high-expression group (*N* = 252), and the samples below the median expression level were set as low-expression group (*N* = 252) ([@B50]). Then, we explored the relationship between the SPP1 expression level and the prognosis of LUAD.

Statistical Analysis {#S2.SS8}
--------------------

Mann--Whitney *U* test was used to compare the SPP1 expression in LUAD tissues and normal lung tissues from the GEO database. The relevance between clinicopathological characteristics and the SPP1 mRNA expression level was analyzed by χ^2^ test with the SPSS software (version 20). For the LUAD samples in GSE68465, according to the expression level of SPP1, the samples above the median expression level were set as high-expression group (*N* = 222), and the samples below the median expression level were set as low-expression group (*N* = 221) ([@B51]; [@B13]). Using the GraphPad Prism software (version 8) and Kaplan--Meier method, the relationship between the overall survival rate and the SPP1 expression level was analyzed. Univariate Cox regression model was conducted using SPSS software (version 20). Statistical significance was set as *P* \< 0.05.

Results {#S3}
=======

SPP1 mRNA Expressions in Normal Lung Tissues and Tumor {#S3.SS1}
------------------------------------------------------

NSCLC ranked ninth among cancer cell lines based on the SPP1 expression according to the data from CCLE database ([Figure 1A](#F1){ref-type="fig"}). In seven studies, the SPP1 mRNA expression levels in LUAD tissues were significantly higher than that in normal lung tissues (*P* \< 0.05). Each study supported the above conclusion ([Figures 1B--H](#F1){ref-type="fig"}).

![**(A)** The messenger RNA (mRNA) expression levels of SPP1 in non-small cell lung cancer (NSCLC) and other cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) database. NSCLC ranked ninth among cancer cell lines based on SPP1 expression. **(B--H)** Comparison of SPP1 mRNA levels in normal lung tissues and lung adenocarcinoma (LUAD) tissues across seven analyses of LUAD, and each study showed that the SPP1 mRNA expression levels in LUAD tissues were significantly higher than that in normal lung tissues.](fgene-11-00547-g001){#F1}

SPP1 Expression at the Protein Level {#S3.SS2}
------------------------------------

Based on the protein expression data from the HPA, the protein expression of SPP1 in LUAD tissues and control normal lung tissues were compared by antibody CAB002212. The SPP1 protein expression in normal lung tissues was "not detected" in two cases. However, the protein expression of SPP1 in LUAD was "medium" in two cases, "low" in three cases, and "not detected" in one case ([Figures 2A,B](#F2){ref-type="fig"}). It was further confirmed that SPP1 protein was highly expressed in LUAD than in normal lung tissues. The survival curves of 262 samples with high SPP1 expression and 238 samples with low SPP1 expression were obtained by analyzing the relevance between the SPP1 mRNA expression and prognosis in the HPA database ([Figure 2C](#F2){ref-type="fig"}). It was found that compared with the SPP1 low-expression group, the overall survival rate of SPP1 high-expression group was significantly lower (log-rank *P* = 0.011).

![**(A)** The protein expression of secreted phosphoprotein 1 (SPP1) was detected in normal lung tissues from the Human Protein Atlas (HPA) database. **(B)** The protein expression of SPP1 was medium in lung adenocarcinoma (LUAD) from the HPA database. **(C)** The survival curves of 262 samples with high SPP1 mRNA expression and 238 samples with low SPP1 mRNA expression in HPA database.](fgene-11-00547-g002){#F2}

Association Between Clinicopathological Characteristics and SPP1 mRNA Expression {#S3.SS3}
--------------------------------------------------------------------------------

The SPP1 mRNA expression level in LUAD tissues was significantly higher than that in normal lung tissues in GSE68465 (*P* = 0.039; [Figure 3A](#F3){ref-type="fig"}). Based on the clinical and pathological information from GSE68465, the SPP1 expression in LUAD was not related to age, T stage, and smoking history (*P* \> 0.05) but related to the gender, N stage, histological grade, and progression and relapse (*P* \< 0.05; [Table 1](#T1){ref-type="table"}). In men, the SPP1 expression levels were higher compared to that in women. In the progression of lymph node metastasis of LUAD, the higher the N stage, the higher the SPP1 expression level. As LUAD progresses or relapses, the SPP1 expression could increase. In the pathological grade, the expression level of SPP1 was higher in lung adenocarcinoma samples whit moderately differentiated. Based on the clinical follow-up data of GSE68465, the overall 5-year survival rates of the SPP1 high-expression group and the SPP1 low-expression group were 50.574 and 59.181%, respectively \[hazard ratio (HR) = 0.7057; 95% CI, 0.5467--0.9109; *P* = 0.008; [Figure 3B](#F3){ref-type="fig"}\]. By univariate Cox regression model, we concluded that age, gender, T stage, N stage, and SPP1 had an impact on overall survival rate of LUAD patients (*P* \< 0.05; [Supplementary Table S1](#TS1){ref-type="supplementary-material"}).

![**(A)** The messenger RNA (mRNA) expression of secreted phosphoprotein 1 (SPP1) in lung adenocarcinoma (LUAD) and normal lung tissues based on GSE68465. **(B)** The overall survival rates of the SPP1 high-expression group and the SPP1 low-expression group in LUAD based on GSE68465.](fgene-11-00547-g003){#F3}

###### 

Associations between SPP1 expression and clinicopathological factors of patients with LUAD (based on GSE68465).

                             **Total number**   **SPP1**                  
  -------------------------- ------------------ ---------- ----- -------- -------
  Gender                     443                                 6.340    0.012
  Male                                          98         125            
  Female                                        123        97             
  Age                        443                                 0.435    0.510
  \<60 years                                    67         61             
  ≥60 years                                     154        161            
  T stage                    441                                 6.468    0.091
  T1                                            72         78             
  T2                                            133        118            
  T3                                            14         14             
  T4                                            2          10             
  N stage                    440                                 13.486   0.001
  N0                                            158        141            
  N1                                            48         40             
  N2                                            14         39             
  Progression or relapse     362                                 5.485    0.019
  Yes                                           96         109            
  No                                            93         64             
  Histological grade         436                                 9.195    0.010
  Well differentiated                           40         20             
  Moderate differentiation                      93         116            
  Poorly differentiated                         84         83             
  Smoking history            349                                 2.357    0.125
  Yes                                           170        130            
  No                                            22         27             

The Relationship Between SPP1 and Immune Infiltrates {#S3.SS4}
----------------------------------------------------

Based on the TIMER database, the relationship between SPP1 expression and CD4^+^ T cell, neutrophil, macrophage, and dendritic cell infiltration was weak in LUAD (*P* \< 0.05; [Figure 4A](#F4){ref-type="fig"}). According to the Kaplan--Meier plots for immune infiltration and SPP1 expression, the survival rate of high level of B cell and dendritic cell infiltration group was significantly higher than that of low level of infiltration group (*P* \< 0.05). At the same time, the group with low SPP1 expression had significantly higher survival rates than that group with high SPP1 expression (*P* \< 0.05; [Figure 4B](#F4){ref-type="fig"}).

![**(A)** The relationship between secreted phosphoprotein 1 (SPP1) expression and six immune infiltrates in lung adenocarcinoma (LUAD) from the Tumor Immune Estimation Resource (TIMER). **(B)** The survival rate of SPP1 and the LUAD immune subsets from the TIMER.](fgene-11-00547-g004){#F4}

SPP1 Is an Independent Prognostic Marker for LUAD Patients {#S3.SS5}
----------------------------------------------------------

The clinical relevance of LUAD immune subsets was explored by a multivariable Cox proportional hazards model, and SPP1 could be considered as an independent prognostic marker for LUAD patients (HR = 1.150; 95% CI, 1.048--1.261; *P* = 0.003; [Table 2](#T2){ref-type="table"}).

###### 

Multivariate Cox proportional hazard regression analyses of the relationship between clinicopathological characteristics and overall survival in LUAD from the Tumor Immune Estimation Resource (TIMER).

  **Variables**   **HR**   **95% CI**       ***P* value**
  --------------- -------- ---------------- ---------------
  Age             1.017    1.000--1.035     0.046
  Gender (male)   0.826    0.591--1.154     0.262
  Stage2          2.350    1.548--3.567     0.000
  Stage3          2.999    1.969--4.569     0.000
  Stage4          3.789    2.068--6.941     0.000
  Purity          1.471    0.642--3.370     0.362
  B_cell          0.040    0.003--0.612     0.021
  CD8_Tcell       2.344    0.341--16.136    0.387
  CD4_Tcell       36.137   2.255--579.010   0.011
  Macrophage      0.588    0.035--9.888     0.712
  Neutrophil      0.262    0.005--13.909    0.508
  Dendritic       0.333    0.077--1.444     0.142
  SPP1            1.150    1.048--1.261     0.003

Gene Set Enrichment Analysis {#S3.SS6}
----------------------------

The effect of SPP1 expression on biological pathway was analyzed by GSEA based on GSE68465. The results of GSEA indicated that samples with high SPP1 expression enriched in protein secretion, mTORC1 signaling, angiogenesis, and glycolysis pathway ([Table 3](#T3){ref-type="table"} and [Figure 5](#F5){ref-type="fig"}).

###### 

Gene set enrichment in SPP1 high-expression phenotype (based on GSE68465).

  **Gene set name**   **Normalized enrichment score**   **False discovery Rate *q* value**   **Normalized *P* value**
  ------------------- --------------------------------- ------------------------------------ --------------------------
  PROTEIN_SECRETION   0.538                             0.211                                0.010
  MTORC1_SIGNALING    0.518                             0.127                                0.006
  ANGIOGENESIS        0.566                             0.138                                0.021
  GLYCOLYSIS          0.422                             0.202                                0.020

![Gene set enrichment analysis (GSEA) showed that the samples with high secreted phosphoprotein 1 (SPP1) expression enriched in **(A)** protein secretion, **(B)** mTORC1 signaling, **(C)** angiogenesis, and **(D)** glycolysis pathway.](fgene-11-00547-g005){#F5}

Validation in TCGA Dataset {#S3.SS7}
--------------------------

From the TCGA-LUAD data, the SPP1 mRNA expression in normal lung tissue was significantly lower than that in LUAD samples (*P* \< 0.001; [Figure 6A](#F6){ref-type="fig"}). Based on the clinical follow-up data of GSE68465, the overall 5-year survival rates of the SPP1 high-expression group and the SPP1 low-expression group were 33.755 and 45.329%, respectively (HR = 0.7088; 95% CI, 0.5298--0.9483; log-rank *P* = 0.020; [Figure 6B](#F6){ref-type="fig"}). According to the clinical and pathological information from TCGA-LUAD, the SPP1 expression in LUAD was related to the N stage. As the N stage progresses, the expression level of SPP1 is higher than before (*P* \< 0.05; [Supplementary Table S2](#TS2){ref-type="supplementary-material"}). The analysis results obtained using TCGA-LUAD data were basically consistent with the results obtained using GSE68465.

![**(A)** The messenger RNA (mRNA) expression of secreted phosphoprotein 1 (SPP1) in lung adenocarcinoma (LUAD) and normal lung tissues based on The Cancer Genome Atlas (TCGA)-LUAD. **(B)** The overall survival rates of the SPP1 high-expression group and the SPP1 low-expression group in LUAD based on TCGA-LUAD.](fgene-11-00547-g006){#F6}

Discussion {#S4}
==========

SPP1 is a secreted calcium binding phosphorylation protein, which can activate many kinds of signaling pathways, promote tumor growth, metastasis, and angiogenesis and regulate the expression of various carcinogenic and angiogenic molecules. More and more studies have shown that SPP1 is closely related to the migration and metastasis of the malignant tumors. In multiple malignant tumors such as gastric, esophageal, and colorectal cancers, SPP1 could be detected to have a significantly high expression. Moreover, the SPP1 expression level was significantly higher in tumors with higher malignancy than that in tumors with lower malignancy ([@B28]; [@B58]; [@B8]; [@B1]). [@B58] found that SPP1 could activate the epithelial--mesenchymal transition (EMT) pathway to promote the metastasis of colorectal cancer. [@B8] detected the potential functional marker single nucleotide polymorphism (tagSNP) of SPP1 by PCR and found that the frequency of SPP1 rs4754 genotype was significantly different from that of the control group, and the rs4754 TT genotype increased the risk of gastric cancer. [@B40] found that SPP1 was upregulated in tumor tissues and plasma of patients with head and neck cancer, and the overexpression of SPP1 or the elevated level of plasma SPP1 in head and neck cancer tissues was associated with high malignancy and poor prognosis. These studies showed that SPP1 played a prominent role in the development of multiple tumors.

[@B12] found that loss of SPP1 expression could be protective for mice harboring KRASG12D-driven LUAD; however, overexpression of SPP1 could promote the occurrence of early tumors and cause tumor-related inflammation. [@B62] detected that SPP1 was highly expressed in tumor-associated macrophages (TAMs) and LUAD tissues, and SPP1 played a role in lung cancer escape and mediating macrophage polarization. [@B55] detected that inhibiting the SPP1 expression in lung cancer may overcome the resistance of second-generation EGFR TKI, and the expression of SPP1 may lead to increased resistance of lung cancer. These studies indicated that there was a close relationship with SPP1 and LUAD; SPP1 affecting the mechanism of lung adenocarcinoma needs to be further explored.

In this study, bioinformatics analysis revealed that SPP1 was highly expressed in LUAD tissues, which was related to poor prognosis. At the cell line level, NSCLC ranked ninth among cancer cell lines based on SPP1 expression. At the mRNA and protein level, we confirmed that SPP1 expression in LUAD tissues was higher than that in normal control based on the data from CCLE, GEO and HPA databases. We further verified the difference in SPP1 between LUAD and normal lung tissues, and the prognosis of LUAD samples by GSE68465. We found that the expression of SPP1 was related to gender, N stage, histological grade, and progression and relapse. Moreover, age, gender, T stage, N stage, and SPP1 had an impact on overall survival for LUAD patients. Then, we found that, compared to the SPP1 low-expression group, the overall survival rate of SPP1 high-expression group was significantly lower. The relationship between SPP1 expression and CD4^+^ T cell, macrophage, neutrophil, and dendritic cell infiltration was weak in LUAD from the TIMER database. Meanwhile, SPP1 could be considered as an independent prognostic marker for LUAD by a multivariable Cox proportional hazards model. The results indicated that samples with high SPP1 expression enriched in protein secretion, mTORC1 signaling, angiogenesis, and glycolysis pathway by GSEA based on GSE68465. The analysis results obtained using TCGA-LUAD data were basically consistent with the results obtained using GSE68465.

In the lung cancer microenvironment, tumor-infiltrating immune cells can not only attack and kill lung cancer cells to inhibit tumor progression but also screen tumor cells that were more suitable for survival in immune-active hosts or change the tumor microenvironment and promote tumor progression ([@B35]). CD4^+^ T cells in the tumor microenvironment were divided into two subgroups of Th1 cells and Th2 cells according to the phenotype. The interaction between lung cancer cells, Th1 cells, and Th2 cells led to an imbalance of Th1/Th2 cell proportion, increasing the risk of lung cancer progression ([@B6]). Activated Th1 cells released cytokines such as tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), and interleukin (IL)-2, which can inhibit tumor progression by mediating cellular immunity, inducing apoptosis of tumor cells, and inhibiting the formation of neovascularization in tumors, while activated Th2 cells released IL-4, IL-5, IL-10, and IL-13 and other cytokines, through the mediator fluid immunity, and played a role in promoting tumor growth ([@B17]; [@B33]). The M2 phenotype TAMs participated in complex autocrine and paracrine pathways and promoted tumor progression ([@B24]). Dendritic cells, as powerful antigen-presenting cells, were the central link for initiating, regulating, and maintaining immune responses, and played a key role in inducing antilung cancer immune responses ([@B41]). [@B62] detected that SPP1 was highly expressed in TAMs and LUAD tissues. Based on the above researches, the mechanism by which SPP1 promotes the development of LUAD may be closely related to changes in the immune microenvironment.

SPP1 may be involved in the secretion of exosomes of tumor cells. Tumor cells exchanged materials and information with the surrounding microenvironment by releasing a large number of exosomes, microbubbles or microparticles, and apoptotic bodies, which participated in promoting tumor growth and progression ([@B32]; [@B34]). Excessive activation of mTOR signaling pathway was ubiquitous in tumor cells. mTOR activation played an important role in tumor cell growth, protein synthesis, cell metabolism, and other physiological and pathological processes, and its over activation could lead to the proliferation of a variety of cancer cells ([@B14]; [@B31]; [@B42]). [@B39] confirmed that resveratrol could induce autophagy of breast cancer cell MCF-7 by inhibiting the expression of mTOR. Because of the rapid proliferation of tumor cells, the microenvironment was always in a relatively hypoxic state, which was the basis of pathological angiogenesis. Neovascularization provided oxygen and nutrition for tumor growth and transported and removed its metabolic waste, thus supporting tumor survival ([@B15]). Tumor angiogenesis was the key to tumor growth, invasion, and metastasis ([@B10]; [@B18]). [@B56] found that normal cells chose oxidative phosphorylation to provide ATP, while tumor cells preferred glycolysis; even when oxygen was sufficient, tumor cells still provided energy through glycolysis. The change in glycometabolism pathway was one of the differences between tumor cells and normal cells. Tumor cells could produce more nucleotides, fatty acids, proteins, and ATP through enhanced aerobic glycolysis, which provided a material basis for the rapid proliferation of tumor cells ([@B30]). At the same time, it could reduce the production of reactive oxygen species, improve the antioxidant capacity of cells, and reduce the apoptosis of cells. In addition, aerobic glycolysis could produce a lot of lactic acid, creating an acidic microenvironment for tumor cells, which was conducive to the invasion and metastasis of tumor cells ([@B29]). Based on the above researches, SPP1 may be involved in protein secretion, mTORC1 signaling, angiogenesis, and glycolysis pathways, which in turn affect the occurrence and development of LUAD.

Although there is no research confirmed at present, according to the results of bioinformatics analysis, it can be concluded that SPP1 has the potential to be a new target for molecular targeted therapy of LUAD. However, due to the lack of necessary experimental conditions, the specific mechanism of SPP1 in the development of LUAD has not been thoroughly explored. The research group will continue to explore the specific role of SPP1 in the development of LUAD after the experimental conditions are perfect.

Conclusion {#S5}
==========

To sum up, we found that SPP1 was highly expressed in LUAD, which was closely related to the clinical characteristics of LUAD patients. Compared with the SPP1 low-expression samples, the overall survival rate of the SPP1 high-expression samples was significantly lower. At the same time, we explored the relationship between SPP1 and immune infiltration and elucidated that SPP1 enriched in protein secretion, mTORC1 signaling, angiogenesis, and glycolysis pathway. Therefore, SPP1 can not only affect the occurrence and development of LUAD but also be an independent prognostic marker of LUAD. SPP1 is expected to become a new target for molecular targeted therapy.
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